(Reuters) - Genetic testing specialist Qiagen
But while Qiagen could boost profits by focusing on products identifying the coronavirus it will continue to bet on growth in its molecular diagnostics business, rather than uncertain one-off gains, CEO Thierry Bernard told a results conference call.
Already a subscriber? Log in.
Subscribe or renew your subscriptions to win prizes worth up to RM68,000!
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!